** Shares of cancer therapy maker Legend Biotech up about 8% at $46.80 before the bell
** Board of Genscript , a key shareholder of LEGN, has "resolved to deconsolidate the Legend Group", the life sciences firm said on Tuesday
** Genscript said that after the deconsolidation, it will account for its investment in LEGN using equity method
** Genscript expects to recognize a one-time gain related to the deconsolidation
** As of Dec. 31, 2023, Genscript owned about 174.5 million shares of LEGN
** As of last close, LEGN down about 28% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。